X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1812) 1812
Book Chapter (19) 19
Magazine Article (9) 9
Newsletter (4) 4
Book / eBook (2) 2
Web Resource (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1319) 1319
index medicus (1154) 1154
hiv infections - drug therapy (840) 840
hiv (534) 534
hiv integrase inhibitors - therapeutic use (522) 522
integrase (501) 501
pharmacology & pharmacy (444) 444
infectious diseases (427) 427
female (415) 415
male (415) 415
hiv-1 - drug effects (374) 374
hiv infections - virology (350) 350
raltegravir (350) 350
animals (346) 346
human immunodeficiency virus--hiv (343) 343
anti-hiv agents - therapeutic use (338) 338
adult (308) 308
raltegravir potassium (307) 307
hiv integrase inhibitors - pharmacology (304) 304
antiviral agents (290) 290
middle aged (263) 263
antiretroviral therapy (248) 248
virology (241) 241
microbiology (229) 229
hiv infection (226) 226
immunology (221) 221
mutation (221) 221
integrase inhibitors (216) 216
drug therapy (210) 210
hiv-1 (210) 210
pyrrolidinones - therapeutic use (208) 208
hiv-1 - genetics (207) 207
mice (202) 202
research (197) 197
hiv integrase - metabolism (196) 196
antiretroviral drugs (194) 194
drug resistance (194) 194
anti-hiv agents - pharmacology (191) 191
drug resistance, viral (191) 191
infection (180) 180
analysis (173) 173
aids (171) 171
health aspects (168) 168
hiv integrase - genetics (168) 168
multidisciplinary sciences (168) 168
hiv-1 integrase (167) 167
viral load (164) 164
dolutegravir (162) 162
hiv integrase inhibitors - adverse effects (160) 160
double-blind (159) 159
treatment outcome (159) 159
integrase inhibitor (154) 154
inhibitors (153) 153
protease inhibitors (151) 151
medicine (150) 150
immunodeficiency-virus type-1 (149) 149
biochemistry & molecular biology (148) 148
chemistry, medicinal (146) 146
research article (146) 146
pharmacokinetics (144) 144
hiv-1 - enzymology (143) 143
drug therapy, combination (142) 142
in-vitro (142) 142
proteins (142) 142
heterocyclic compounds, 3-ring - therapeutic use (141) 141
integrases - metabolism (141) 141
human immunodeficiency virus (138) 138
hiv integrase inhibitors - chemistry (137) 137
therapy (134) 134
reverse transcriptase inhibitors - therapeutic use (131) 131
replication (128) 128
science (127) 127
viruses (127) 127
drug design (126) 126
acquired immune deficiency syndrome--aids (123) 123
highly active antiretroviral therapy (122) 122
hiv integrase - chemistry (119) 119
resistance (119) 119
antiretroviral agents (118) 118
hiv integrase inhibitors - administration & dosage (117) 117
human-immunodeficiency-virus (117) 117
dna (114) 114
genetic aspects (112) 112
care and treatment (111) 111
infections (109) 109
safety (108) 108
integrases - genetics (107) 107
hiv-1 - physiology (105) 105
aids/hiv (104) 104
deoxyribonucleic acid--dna (103) 103
hiv protease inhibitors - therapeutic use (103) 103
cd4 lymphocyte count (101) 101
elvitegravir (101) 101
models, molecular (101) 101
anti-hiv agents - administration & dosage (100) 100
drug interactions (98) 98
biology (97) 97
drug resistance, viral - genetics (96) 96
pharmacology (96) 96
dosage and administration (95) 95
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1782) 1782
Spanish (32) 32
German (17) 17
Japanese (13) 13
French (8) 8
Chinese (4) 4
Russian (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of infectious diseases, ISSN 1537-6613, 2015, Volume 212, Issue 8, pp. 1241 - 1249
.... At week 96, the mean percentage changes from baseline in spine and hip BMDs were similar in the protease inhibitor (PI) arms (spine: -4.0... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 9, pp. e410 - e420
.... We aimed to assess the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared... 
Infectious Disease | UNITED-STATES | INFECTIOUS DISEASES | TENOFOVIR DISOPROXIL FUMARATE | TREATMENT-NAIVE | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | INITIAL TREATMENT | GENDER | SEX-DIFFERENCES | IMMUNOLOGY | HIV-1 INFECTION | ADVERSE EVENTS | Atazanavir Sulfate - administration & dosage | Humans | RNA, Viral - blood | Tenofovir - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Atazanavir Sulfate - adverse effects | Viral Load | Quinolones - adverse effects | Ritonavir - adverse effects | Quinolones - therapeutic use | Ritonavir - therapeutic use | Adult | Female | Emtricitabine - administration & dosage | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Ritonavir - administration & dosage | Tenofovir - therapeutic use | HIV Infections - virology | Cobicistat - administration & dosage | International Cooperation | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Atazanavir Sulfate - therapeutic use | Quinolones - administration & dosage | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Cobicistat - adverse effects | HIV Infections - drug therapy | Cobicistat - therapeutic use
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 10/2007, Volume 46, Issue 2, pp. 125 - 133
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 814 - 822
Journal Article
Journal of antimicrobial chemotherapy, ISSN 1460-2091, 2017, Volume 72, Issue 6, pp. 1752 - 1759
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Evidence-based medicine | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2008, Volume 14, Issue 7, pp. 762 - 766
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 01/2017, Volume 56, Issue 1, pp. 25 - 40
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e52562
.... The purpose of this study was to review the evidence for integrase inhibitor use in clinical settings. Methods... 
CROSS-RESISTANCE PROFILE | TWICE-DAILY RALTEGRAVIR | NAIVE HIV-1-INFECTED PATIENTS | COMBINATION THERAPY | MULTIDISCIPLINARY SCIENCES | TREATMENT-EXPERIENCED PATIENTS | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | OPTIMIZED BACKGROUND THERAPY | ANTIRETROVIRAL TREATMENT | LONG-TERM EFFICACY | HIV-1 - drug effects | HIV Infections - virology | Humans | Reverse Transcriptase Inhibitors - pharmacology | Treatment Outcome | Clinical Trials as Topic | Reverse Transcriptase Inhibitors - adverse effects | Protease Inhibitors - pharmacology | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Protease Inhibitors - adverse effects | Drug Resistance, Viral - drug effects | HIV Infections - drug therapy | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Load - drug effects | Highly active antiretroviral therapy | Usage | Protease inhibitors | Proteases | Respiratory agents | Drug resistance | HIV (Viruses) | Integrase | Antiretroviral drugs | Therapy | Clinical trials | Systematic review | Proteinase inhibitors | Patients | Antiretroviral therapy | Switching | Studies | Immunology | Motivation | Acquired immune deficiency syndrome--AIDS | Reproduction (copying) | Antiretroviral agents | Human immunodeficiency virus--HIV | Failure analysis | Quality control | Quality assessment | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
AIDS (London), ISSN 0269-9370, 2010, Volume 24, Issue 11, pp. 1697 - 1707
Journal Article